As a result, the first international consensus group has recommended that severely affected patients, which include those patients with Hb < 8 g/dL, patients with Evans’ syndrome, and patients with atypical AIHA which includes IgA‐mediated, DAT‐negative and mixed, should be considered for rituximab plus prednisolone combination therapy in the first line [7, 11]. Here, CD79A is linked to autoimmune hemolytic anemia.